Navigation Links
Pitt researchers find candidates for new HIV drugs
Date:10/13/2009

PITTSBURGH, Oct. 13 While studying an HIV protein that plays an essential role in AIDS progression, researchers at the University of Pittsburgh School of Medicine have discovered compounds that show promise as novel treatments for the disease.

HIV drug discovery efforts have met with little success in finding compounds that interact with an important HIV virulence factor, called Nef, because it lacks biochemical activity that can be directly measured, explained Thomas E. Smithgall, Ph.D., William S. McEllroy Professor and Chair, Department of Microbiology and Molecular Genetics, and senior author of the paper, which was published last week in the early, online version of ACS Chemical Biology.

To get around that problem, Dr. Smithgall's team developed an assay to measure Nef function indirectly by coupling it to another protein, called Hck, which Nef activates in HIV-infected cells. Because Hck activity can be easily measured, the investigators were able to use it as a reporter for Nef activity in an automated high-throughput screening process. In collaboration with the University of Pittsburgh Drug Discovery Institute, they screened a library of 10,000 chemical compounds against the coupled proteins to see which ones influenced Nef-induced activation of Hck.

After further testing, they confirmed that three compounds inhibited the activity of the Nef-Hck complex and, more importantly, all of them also interfered with HIV replication. One compound was so effective that it suppressed HIV replication to undetectable levels in cell culture experiments.

"So we now have a way to rapidly and efficiently screen for inhibitors of Nef signaling through Hck," Dr. Smithgall said. "But the surprise was that some of those inhibitors also showed strong antiviral activity in cell culture models."

There is evidence that people infected with HIV variants that have mutations in the Nef gene take substantially longer to develop disease symptoms or AIDS, he said. In animal models, disrupting the production of Nef from the virus or its interaction with Hck also delays or prevents disease symptoms. The next challenge for the researchers will be to determine whether these compounds also interfere with progression of AIDS-like disease in animal models by blocking Nef function.

"Most current therapies for HIV infection use drugs that interfere with the function of viral enzymes such as reverse transcriptase or with the interaction of the virus and the host cell," Dr. Smithgall said. "Targeting Nef represents an entirely new approach that could be useful to deal with issues such as drug-resistant HIV strains, and may slow the progression to AIDS."

He added that Nef is just one of several so-called "accessory proteins" encoded by HIV which are important virulence factors in AIDS. Inhibitory compounds against some of the others might be revealed using a similar coupled protein approach for high throughput screening.


'/>"/>

Contact: Anita Srikameswaran
SrikamAV@upmc.edu
412-578-9193
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related medicine news :

1. Researchers discover mechanism that helps humans see in bright and low light
2. New effort to battle antibiotic resistance rallies researchers throughout Harvard University
3. Researchers report benefits of new standard treatment study for rare pediatric brain cancer
4. Researchers identify genes associated with onset age of Parkinsons disease
5. BUSM researchers identify better laser for treating facial spider veins
6. Toronto researchers discover novel circulation in human eye, new glaucoma treatment target
7. Researchers find demand for cosmetic and surgical procedures in dermatologic surgery rising rapidly
8. Using synthetic evolution to study the brain: Researchers model key part of neurons
9. Researchers at Boston University School of Medicine incorporate multisite geriatric clerkship
10. Researchers use computational models to study fear
11. Researchers develop an integrated treatment for veterans with chronic pain and posttraumatic stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... Massachsetts (PRWEB) , ... May 26, 2017 , ... ... will gather at Boston CEO 2017 on May 30th and 31st at The ... networking forum for leading executives in the life sciences, offering exclusive access to ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of community health data reveals ... located in the Midwest. With the average cost of healthcare rising and the U.S. ... both the quality and affordability of where they live. An annual 2017 report looked ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... After raising ... Antzy Top gadget will continue to be available at a discounted crowdfunding price on ... with stress wherever they are, I also wanted to bring a fidget toy to ...
(Date:5/26/2017)... ... 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon specializing in ... post on insurance options. If a Bay Area patient has to search for a ... money. Visiting an in-network provider for a second opinion can ensure a patient receives ...
(Date:5/26/2017)... ... ... Happened in the Garden of Eden”: retells the stories of three Bible figures in modern ... author, Penelope Colt, mother, trader, horse farmer, artist and a former GM journeyman. Born ... At six, they moved to Dayton, Ohio, where Penny graduated high school. At sixteen, ...
Breaking Medicine News(10 mins):
(Date:5/6/2017)... N.Y. , May 5, 2017  Hill-Rom Holdings, ... will add approximately 100,000 square feet to its Welch ... September 2016 its commitment to bring more than 100 ... , where Welch Allyn has maintained a significant presence ... help accommodate these new positions, a large portion of ...
(Date:5/4/2017)... CAESAREA, Israel , May 4, 2017  DarioHealth ... with mobile health and big data solutions, today announced ... an A&D Company, and STI Technologies Limited to lower ... effective immediately. Through STI,s innoviCares card, which is available ... , DarioHealth customers will be eligible for additional ...
(Date:5/3/2017)... 3, 2017  Getinge, a leading global provider ... enhancement and cost efficiency within healthcare and life ... contemporary practice demonstrating that intra-aortic balloon counterpulsation (IABC) ... ill patients. The single-center, retrospective, observational study showed ... MEGA ® 50cc intra-aortic balloon (IAB) in ...
Breaking Medicine Technology: